Atıf İçin Kopyala
DURUSU TANRIÖVER M., Doganay H. L., AKOVA M., Guner H. R., Azap A., AKHAN S., ...Daha Fazla
LANCET, cilt.398, sa.10296, ss.213-222, 2021 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
398
Sayı:
10296
-
Basım Tarihi:
2021
-
Doi Numarası:
10.1016/s0140-6736(21)01429-x
-
Dergi Adı:
LANCET
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Psycinfo, Veterinary Science Database
-
Sayfa Sayıları:
ss.213-222
-
Hacettepe Üniversitesi Adresli:
Evet
Özet
Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.